Legato Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Legato Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,035	Closed	-$746K	–	767
2025 Q4	$746K	Buy	16,035 +10,350	+182%	+$461K	0.06%	436
2025 Q3	$237K	Buy	+5,685	New	+$182K	0.03%	505
2025 Q1	–	Sell	-29,554	Closed	-$1.51M	–	581
2024 Q4	$1.51M	Buy	29,554 +4,057	+16%	+$227K	0.2%	173
2024 Q3	$1.3M	Buy	25,497 +6,482	+34%	+$334K	0.16%	224
2024 Q2	$852K	Buy	19,015 +9,135	+92%	+$422K	0.11%	297
2024 Q1	$462K	Sell	9,880 -1,695	-15%	-$66.3K	0.06%	453
2023 Q4	$412K	Buy	+11,575	New	+$355K	0.05%	449

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Legato Capital Management's CRNX Position: Q1 2026 in Review

Legato Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 16,035 shares — an estimated $746K sold.

Legato Capital Management first reported a position in CRNX in Q4 2023 and held it in 7 quarters. The position peaked at $1.51M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Legato Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Legato Capital Management sold 16,035 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $746K.
Legato Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Legato Capital Management's Crinetics Pharmaceuticals position peaked at $1.51M in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.